The present invention relates to a pharmaceutical combination which comprises (a) a JAK inhibitor compound, (b) a CDK inhibitor, and (c) a PIM kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia a pharmaceutical composition comprising such a combination the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use and to a method of treatment of a mammal, especially a human.
